Advertisement
Singapore markets close in 7 hours 43 minutes

  • Straits Times Index

    3,257.74
    -35.39 (-1.07%)
     

  • Nikkei

    37,966.46
    -493.62 (-1.28%)
     

  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     

  • FTSE 100

    8,040.38
    -4.43 (-0.06%)
     

  • Bitcoin USD

    64,447.23
    -2,297.14 (-3.44%)
     

  • CMC Crypto 200

    1,394.49
    -29.61 (-2.08%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • Dow

    38,460.92
    -42.77 (-0.11%)
     

  • Nasdaq

    15,712.75
    +16.11 (+0.10%)
     

  • Gold

    2,330.80
    -7.60 (-0.33%)
     

  • Crude Oil

    82.71
    -0.10 (-0.12%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • FTSE Bursa Malaysia

    1,573.81
    +2.33 (+0.15%)
     

  • Jakarta Composite Index

    7,174.53
    -7,110.81 (-49.78%)
     

  • PSE Index

    6,572.75
    +65.95 (+1.01%)
     

2 Beaten-Down Biotech Stocks That Could Be Great Long-Term Plays

Prosper Junior Bakiny, The Motley Fool
·5-min read
2 Beaten-Down Biotech Stocks That Could Be Great Long-Term Plays

With that in mind, let's look at two healthcare stocks that have performed poorly over the past year but have a chance to bounce back big: Gilead Sciences (NASDAQ: GILD) and Incyte (NASDAQ: INCY). Biotech giant Gilead Sciences is still feeling the aftereffects of a regulatory setback related to filgotinib, its potential medicine for rheumatoid arthritis. The company hoped that it would become a blockbuster product, but the U.S. Food and Drug Administration (FDA) had other plans.

Continue reading